Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.006.82%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 57.50K | 336.10K | 350.40K | 460.10K | 657.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.50K | 336.10K | 350.40K | 460.10K | 657.60K |
| Cost of Revenue | 1.74M | 1.81M | 2.11M | 2.19M | 1.79M |
| Gross Profit | -1.68M | -1.48M | -1.76M | -1.73M | -1.13M |
| SG&A Expenses | 3.39M | 3.45M | 4.37M | 4.00M | 3.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.17M | 5.30M | 6.56M | 6.26M | 5.43M |
| Operating Income | -5.12M | -4.97M | -6.21M | -5.80M | -4.77M |
| Income Before Tax | -5.64M | -5.51M | -6.73M | -6.43M | -5.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.64 | -5.51 | -6.73 | -6.43 | -5.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 63.30K | 74.30K | 101.10K | 88.80K | 51.10K |
| Net Income | -5.58M | -5.43M | -6.63M | -6.34M | -5.37M |
| EBIT | -5.12M | -4.97M | -6.21M | -5.80M | -4.77M |
| EBITDA | -5.11M | -4.96M | -6.21M | -5.80M | -4.77M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Average Diluted Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |